Skf38393 hydrobromide

All dopamine pharmacological modulators, except for antagonists 2-CMDO (2-Chloro-11-(4-methylpiperazino)dibenz(Z)[b,f]oxepin maleate), were injected at 1 mg/kg body weight^{7 (link)} intraperitoneally (i.p.) into nursing dams on day of birth and P2, then directly into pups until P8. 2-CMDO was injected into pups P5-P8 at 2 mg/kg body weight. Injection was done in dim red light one hour before lights on. Dopamine agonist SKF38393 hydrobromide; high affinity D₂ antagonist L-741626; dopamine transporter 1 inhibitor, GBR12909 dihydrochloride; 2-CMDO were all purchased from Tocris Biosciences. For experiments with Pdgfb-icreERT2 mouse lines, 2 mg Tamoxifen was injected into nursing dams on the day of birth and on P2 to activate tamoxifen-dependent cre.

(±)-2,5-Dimethoxy-4-iodoamphetamine hydrochloride (DOI), morphine sulphate pentahydrate and naloxone hydrochloride dihydrate were purchased from Millipore Sigma. (±)-SKF38393 hydrobromide and M100907 were purchased from Tocris. All drugs were dissolved in saline (0.9 % NaCl) to the appropriate volume (5-10 μl/g) and concentration for administration (i.p.). The hydrochloride salt of M100907 was formed in situ by addition of 1 eq. of HCl. Vehicle-treated condition denotes injection of saline (i.p.) to the equivalent volume of the drug administered.

Progesterone (P4; #P6149), 17P-estradiol (estradiol, or E2; #E8875) were from Merck; SKF 38393 hydrobromide (#0922) and RU486 (mifepristone; #1479) were from Tocris. Pharmacological treatment of cells was performed directly into B27 medium. Drugs were diluted from stock solutions to final concentration in B27 medium; final solvent amount was <0.01%. Vehicle condition consisted of diluting DMSO in the same manner as drugs.